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Small-Molecule Activators of Glucose-6-phosephate 
Dehydrogenase (G6PD) Bridging the Dimer Interface 
Andrew G. Raub, [a,b] Sunhee Hwang,[a] Naoki Horikoshi,[c,d,e] Anna D. Cunningham,[a,f] Simin 
Rahighi,[d,e,g] Soichi Wakatsuki,[d,e] and Daria Mochly-Rosen*[a] 
 
Abstract: We have recently identified AG1, a small-molecule 
activator that functions by promoting oligomerization of glucose-6-
phosphate dehydrogenase (G6PD) to the catalytically competent 
forms. Biochemical experiments indicate activation of G6PD by the 
original hit molecule (AG1) is noncovalent and that one C2-symmetric 
region of the G6PD homodimer is important for ligand function. 
Consequently, the disulfide in AG1 is not required for activation of 
G6PD and a number of analogs were prepared without this reactive 
moiety. Our Study supports a mechanism of action whereby AG1 
bridges the dimer interface at the structural nicotinamide adenine 
dinucleotide phosphate (NADP+)-binding sites of two interacting 
G6PD monomers. Small molecules that promote G6PD 
oligomerization have the potential to provide a first-in-class treatment 
for G6PD deficiency. This general strategy could be applied to other 
enzyme deficiencies where control of oligomerization can enhance 
enzymatic activity and/or stability. 
Protein-protein interactions (PPIs) underpin the vast 
signaling networks essential for cellular functions. The 
interactome, estimated at 650,000,1 is an area ripe for modulating 
disease pathogenesis.2 Beyond signaling events, the interactome 
includes quaternary structural interactions between proteins, 
which regulate enzyme stability, activity, and function.3 However, 
targeting PPIs with small molecules has long been considered a 
challenging area for drug discovery largely outside the realm of 
the druggable genome.4 Yet, a number of methods such as 
fragment-based drug discovery (FBDD) and rational peptide 
design have produced leads with translational potential.5,6 Efforts 
focused on modulating PPIs have almost entirely centered around 
the inhibition of these interactions,7 but a number of natural 
products and designed ligands derive clinical utility from 
promoting the interaction of two or more proteins.8 
G6PD, an ancient metabolic enzyme present in eukaryotes 
and prokaryotes, catalyzes the first step of the pentose phosphate 
pathway (PPP).9 Products of the PPP are important for the 
biosynthesis of nucleotides and fatty-acids. NADPH is essential 
for generating reduced glutathione, the cell’s primary defense 
against electrophiles and oxidants. Despite the critical role G6PD 
plays in the cell, G6PD deficiency is the second most common 
human enzymopathy; more than 160 single-nucleotide 
substitutions that alter enzymatic activity and/or stability have 
been identified in humans.10 Missense mutations result in a 
variety of clinical phenotypes depending on the nature and 
location of the mutation.11 For example, mutations affecting the 
homodimer interface of G6PD are particularly pathogenic, as only 
the homodimeric and homotetrameric oligomers of G6PD are 
stable and active in vivo.12 G6PD is the only enzyme known to 
have evolved a second NADP+-binding site, close to the dimer 
interface; this second, so called structural site, is essential for 
maintaining activity, stability and oligomeric state of the 
enzyme.13 Mutations that negatively impact binding of NADP+ to 
the structural site also result in pathogenesis. 
Despite the prevalence of G6PD deficiency, commonly 
resulting in mild to severe and chronic hemolytic anemia, no 
therapies currently exist. Previously, we described a small-
molecule activator (Alda-1) of aldehyde dehydrogenase 2 
(ALDH2),14 which activates the most common single-point 
mutation in humans, ALDH2*2 by robustly correcting its structural 
defect.15 Enzyme activation, like PPI stabilization, is a nascent 
pharmacological modality in drug discovery and identifying novel 
mechanisms to enhance enzyme function is of significant clinical 
interest.16,17 Encouraged by the discovery of Alda-1, we set out to 
identify small molecules that enhance the activity of pathogenic 
mutants of G6PD. A biochemical screen was conducted using a 
common, pathogenic mutant (Canton G6PD, R459L) endemic to 
South East Asia.18 A small-molecule activator of several 
pathogenic forms of G6PD (AG1 (2), Scheme 1) was identified 
from the screen, and a detailed mechanistic understanding of 
AG1 was required to further our translational objectives.19  
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Scheme 1. Analogs (3) developed to mimic the primary thiol in 1 are inactive, 
but compounds (4) designed from the pharmacophore of 2 activate G6PD. 
First, we found that analogs (e.g. 3, Scheme 1) prepared 
using the pharmacophore of the structure provided by the vendor 
(1) were inactive. We reasoned that the original molecule 1 can 
undergo oxidation to the disulfide under ambient conditions.20 
When the dimeric molecule AG1 was independently synthesized 
and purified, it recapitulated the activation originally observed in 
the high-throughput screen; a 20% and 60% increase in the 
activity of the wild-type and the Canton mutant, respectively. 
Biochemical experiments indicated that AG1 activates G6PD in a 
non-covalent fashion (Figure S1). 
 
Figure 1. Residues expected to interact favorably with the pharmacophore of 
AG1. (PDB: 1QKI) A) The dimer interface of Canton G6PD located between the 
structural NADP+ (black, designated as NAP-800) with monomers shaded in 
dark and light grey.  B) AG1 (teal) docked to the dimer interface using the Glide 
program in the Schrödinger software suite.  
G6PD is active as a dimer or tetramer, but not as a 
monomer.21 Considering that the active ligand is a dimer, which 
promotes oligomerization in a dose-dependent manner, it seemed 
possible that AG1 spans part of the C2 symmetric dimer interface 
directly stabilizing the G6PD homodimer. Examination of the two 
C2 symmetric regions at the dimer interface identified one region 
which can accommodate the pharmacophore of AG1 (Figure 1A). 
In the G6PD structure, the pyridinium ring of the structural NADP+ 
forms a p-stack with Trp509 (W509), which is approximately 5 
angstroms from Asp421 (D421). This feature is repeated on the 
other monomer, with the two Asp421 separated by 7 angstroms. 
AG1 was docked into this region after removing the unstructured 
C-terminal residues in the enzyme up to Trp509 (Figure 1B). 
Docking of the ligand between the structural NADP+ sites reveals 
an asymmetric pose (Figure 1B), which places the two amines in 
AG1 near Asp421 and Glu419 (E419). A new p-stack of the indole 
in AG1 is formed with the pyridinium ring of the structural NADP+. 
To determine if Asp421 and Glu419 participate in AG1 
binding, a mutational analysis around the two C2 points of 
symmetry was initiated in the Canton G6PD mutant enzyme 
(Figure 2). First, residues which could complement the ligand at 
the C2 symmetric site distal from the structural NADP+ were 
mutated to serve as a control (Figure 2A, bottom). Two anionic 
residues, Asp228 and Glu347, were mutated to alanine (Ala, A). 
Additionally, a hydrophobic pocket in this region near Gly222 
(G222), which could accommodate an indole ring, was mutated to 
an alanine to occlude this space. When AG1 was docked to this 
region of the enzyme, none of the poses generated were 
favorable when compared to the conformation of AG1 docked to 
the structural NADP+ sites. Anionic residues at the predicted site 
between the structural NADP+ (figure 2A, top), Asp421 (red), 
Glu419 (blue) and the double mutant (purple), were mutated to 
alanine. To assess the effect of the mutations, the AC50 
(concentration at half-maximal activation) of AG1 in the relevant 
mutated enzyme was normalized to the AC50 of AG1 in unmutated 
Canton G6PD (figure 2B); values greater than 1 indicate that the 
given mutation attenuated the activation by AG1. Analysis of 
these mutant enzymes indicated that none of the structural 
changes affected the efficacy of the ligand on the site distal to the 
structural NADP+ within error. In contrast, mutations at the dimer 
interface between the structural NADP+, where AG1 was 
predicted to bind, significantly perturbed the AC50 (D421A and 
E419A/D421A). 
 
Figure 2. Mutagenesis of residues expected to interact favorably with the 
pharmacophore of AG1 about both C2 symmetric dimer interfaces suggests the 
region between the structural NADP+ is important for ligand binding. (PDB: 
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1QKI) A) Surface model of G6PD homodimer colored with the mutated residues 
(color coded), AG1 docked in teal (C-terminus deleted to residue 501) and the 
cofactors in black (catalytic NADP+(I), G6P (II), structural NADP+ (III)). B) 
Mutations of anionic residues between the structural NADP+ attenuate activity 
of AG1, but do not have any significant effect on the opposite dimer interface. 
(*p = 0.0075, ***p < 0.0001).  
In addition to generating mutations, which were predicted to 
negatively impact the function of AG1, we predicted that one 
mutation may enhance the activation and/or binding of AG1. In 
the crystal structure of Canton G6PD, Trp509 forms a p-stack with 
the structural NADP+ (Figure 1A). Previous studies demonstrated 
that the presence of the structural NADP+ is crucial for maintaining 
the activity and stability of the enzyme.22 We therefore reasoned 
that removing Trp509 and replacing it with alanine would impair 
G6PD function, but that AG1 should have a greater compensatory 
effect in this mutation. Additionally, because this Trp appears to 
compete with AG1 for binding to the structural NADP+ site, we 
expected that mutating Trp509 should not affect the AC50 
negatively or possibly lower the AC50. The ligand, which had an 
Amax of 1.2-fold in wild-type G6PD and an AC50 = 4.2 µM, activated 
the Trp509Ala mutant enzyme 1.7-fold with an AC50 = 0.8 μM 
(Figure S2). 
Given these results, we reasoned that the disulfide is not 
required for activation and could be replaced with non-reactive 
linkers (Table 1). The preferred method for synthesis of these 
analogs was via the Fukuyama amine synthesis,23 which was 
superior in all cases examined to the initial route of amide 
formation and reduction. As expected, from the analysis of the 
dimer interface and the pharmacophore, shorter linkers – analogs 
6 (4-carbon linker) and 7 (5-carbon linker) – did not function as 
activators but in fact, inhibited enzyme function. Simply replacing 
one atom in 7 with a sulfur atom resulted in conversion of an 
inhibitor to a dose-dependent activator (8). Analogs 5 (3-carbon 
linker), 9 (6-carbon linker), 10 (7-carbon linker) and 11 (8-carbon 
linker) modestly activated the enzyme without prominent 
sigmoidal dose-response curves. Analogs 8, 2, 12 (9-carbon 
linker), 13 (10-carbon linker) and 15 (12-carbon linker) all 
exhibited approximately equal activation (1.6-fold) and sigmoidal, 
dose-dependent activation. Analog 12 was only 2-fold less potent 
than the original disulfide-containing analog 2. Similarly to AG1 
(2), analogs 10, 12 and 13 increased the oligomerization of the 
enzyme (Figure S3). 
 
Table 1. Impact of linker on activation of Canton G6PD. 
 
 
Compound[a] Linker 
AC50 
[µM][a] 
Amax 
[%][a] 
5  -[b] 135%[b] 
6  -[c] -[c] 
7  -[c] -[c] 
8  33 155% 
9  -[b] 119%[b] 
2  3.3 160% 
10  -[b] 123%[b] 
11  -[b] 130%[b] 
12  7.7 160% 
13  15 159% 
14  -[b] 104%[b] 
15  12 146% 
[a] AC50 values were obtained by titration of activators in a biochemical assay 
of Canton G6PD activity with substrate concentrations close to physiologically 
relevant conditions (95% confidence intervals of AC50 values are available in the 
supplementary information). [b] Significant dose-response curves are not 
obtained with these compounds and activation is instead reported at 50 µM. [c] 
Compounds were found to inhibit the enzyme in a dose-dependent manner (SI). 
 
Pharmacological modulation of PPIs, a promising area of 
drug discovery, remains elusive. Moreover, ligands capable of 
stabilizing PPIs are rarer still. As discussed, many pathological 
G6PD mutations have been identified in humans, and AG1 
promotes activation of at least several pathogenic mutants. Our 
current study sheds light on the mechanism by which such a poly-
genotypic activator of G6PD acts. This novel class of molecules 
was originally discovered due to the correct identification of the 
active species (AG1, 2) in samples of the primary thiol 1. 
Mutational analyses and biochemical experiments support a 
mechanism of action whereby AG1 promotes G6PD dimerization 
by bridging two structural NADP+. Efforts to optimize these G6PD 
activators and evaluate their translational potential as a first-in-
class treatment for G6PD deficiency are ongoing. Given the 
omnipresence of PPI regulation in both cellular signaling events 
and enzyme activity/stability, we anticipate that small-molecule 
stabilization of PPIs will be increasingly valuable in drug discovery. 
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A novel class of small-molecule glucose-6-phosphate dehydrogenase (G6PD) 
activators is described. Structural studies support a mechanism of action (MOA) 
whereby the small molecules bind across the dimer interface to promote 
oligomerization to the more catalytically competent enzyme state(s). 
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